Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H29FN6O4 |
Molecular Weight | 484.5233 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(=NC(=N1)N(C)C2=NC=NN2C)C3=CC=C(F)C=C3
InChI
InChIKey=QAMJBKXUQQOLPQ-AQRBRUGDSA-N
InChI=1S/C24H29FN6O4/c1-14(2)21-19(10-9-17(32)11-18(33)12-20(34)35)22(15-5-7-16(25)8-6-15)29-23(28-21)30(3)24-26-13-27-31(24)4/h5-10,13-14,17-18,32-33H,11-12H2,1-4H3,(H,34,35)/b10-9+/t17-,18-/m1/s1
Molecular Formula | C24H29FN6O4 |
Molecular Weight | 484.5233 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:32:26 GMT 2023
by
admin
on
Sat Dec 16 11:32:26 GMT 2023
|
Record UNII |
ZBX3PZ7A0F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
849470-12-8
Created by
admin on Sat Dec 16 11:32:26 GMT 2023 , Edited by admin on Sat Dec 16 11:32:26 GMT 2023
|
PRIMARY | |||
|
ZBX3PZ7A0F
Created by
admin on Sat Dec 16 11:32:26 GMT 2023 , Edited by admin on Sat Dec 16 11:32:26 GMT 2023
|
PRIMARY | |||
|
24809501
Created by
admin on Sat Dec 16 11:32:26 GMT 2023 , Edited by admin on Sat Dec 16 11:32:26 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
BMS-644950:
Rat HMG CoA Reductase= 1.4 nM
Rat Hepatocyte IC50 = 395 nM
Rat Myocyte IC50 = 995 NM
Rat ED50 = 0.11 mpk (myotoxicity window >455x)
Guinea Pig ED50 =28 mpk (no CK elevation)
Thus, an inhibitor with increased selectivity for hepatocytes could potentially result in an improved therapeutic window. Implementation of a strategy that focused on in vitro potency, compound polarity, cell selectivity, and oral absorption, followed by extensive efficacy and safety modeling in guinea pig and rat, resulted in the identification of compound 1b (BMS-644950).
|